: Pfizer’s stock sinks after company slashes $9 billion from outlook on lower COVID product demand

Pfizer and biotech drug maker shares fell after Pfizer slashed its full-year earnings outlook due to a drop in demand for COVID pills and more.

Previous post : Lululemon’s stock to join S&P 500 index
Next post Mutual Funds Weekly: These money and investing tips help you stay in the game no matter the score